Cyprium Therapeutics, our subsidiary company that developed CUTX-101, will retain 100% ownership over any FDA Priority Review Voucher that may be issued at NDA approval. In March 2025, Fortress ...

Cyprium Therapeutics, our subsidiary company that developed CUTX-101, will retain 100% ownership over any FDA Priority Review Voucher that may be issued at NDA approval. Commercial Product Updates ...

Investment in a joint venture company operating a tin mine in Australia; and investments in companies undertaking exploration and development of gold and base metals projects in Australia.